These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27657518)

  • 21. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
    Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
    Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations.
    Cox L; Calderón M; Pfaar O
    Immunotherapy; 2012 Jun; 4(6):601-16. PubMed ID: 22788128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases].
    Malling HJ
    Wien Med Wochenschr; 1999; 149(14-15):410-4. PubMed ID: 10584284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose adjustment practices among allergists for local reactions to immunotherapy.
    Coop CA; Tankersley MS
    Ann Allergy Asthma Immunol; 2007 Jul; 99(1):77-81. PubMed ID: 17650834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey.
    Sikora JM; Tankersley MS;
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):194-197.e4. PubMed ID: 23548531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A national audit of pollen immunotherapy for children in the United Kingdom: patient selection and programme safety.
    Vance GH; Goldring S; Warner JO; Cox H; Sihra B; Hughes S; Gardner J; North J; Roberts G; Proudfoot CA; Clarke A; Luyt DK; Gillies D; Fox AT
    Clin Exp Allergy; 2011 Sep; 41(9):1313-23. PubMed ID: 21762222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allergen immunotherapy practice patterns: a worldwide survey.
    Ponda P; Mithani S; Kopyltsova Y; Sison C; Gupta P; Larenas D; Bonagura VR
    Ann Allergy Asthma Immunol; 2012 Jun; 108(6):454-459.e7. PubMed ID: 22626600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Better documentation through standardized forms: what progress have we made since the 1800s?
    Cox L
    Allergy Asthma Proc; 2004; 25(6):407-22. PubMed ID: 15709452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food Oral Immunotherapy: A Survey Among US Practicing Allergists Conducted as a AAAAI Leadership Institute Project and Work Group Report.
    Anagnostou A; Vickery B
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2330-2334. PubMed ID: 37236350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.
    Burks AW; Calderon MA; Casale T; Cox L; Demoly P; Jutel M; Nelson H; Akdis CA
    J Allergy Clin Immunol; 2013 May; 131(5):1288-96.e3. PubMed ID: 23498595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of subcutaneous allergen immunotherapy.
    Bernstein DI; Epstein TG
    Allergy Asthma Proc; 2022 Jul; 43(4):267-271. PubMed ID: 35818150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Change in Allergy Practice during the COVID-19 Pandemic.
    Ozturk AB; Baççıoğlu A; Soyer O; Civelek E; Şekerel BE; Bavbek S
    Int Arch Allergy Immunol; 2021; 182(1):49-52. PubMed ID: 33059353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report.
    Calderón MA; Casale T; Cox L; Akdis CA; Burks AW; Nelson HS; Jutel M; Demoly P
    Allergy; 2013 Jul; 68(7):825-8. PubMed ID: 24010140
    [No Abstract]   [Full Text] [Related]  

  • 36. Characterisation of systemic reactions to subcutaneous immunotherapy with airborne allergens and classification according to WAO 2010.
    Santos N; Pereira AM; Silva R; Torres da Costa J; Plácido JL
    Allergol Immunopathol (Madr); 2015; 43(1):25-31. PubMed ID: 24661594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New forms of allergy immunotherapy for rhinitis and asthma.
    Nelson HS
    Allergy Asthma Proc; 2014; 35(4):271-7. PubMed ID: 24992546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes.
    Cox L; Esch RE; Corbett M; Hankin C; Nelson M; Plunkett G
    Ann Allergy Asthma Immunol; 2011 Oct; 107(4):289-99; quiz 300. PubMed ID: 21962088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality.
    Linneberg A; Jacobsen RK; Jespersen L; Abildstrøm SZ
    J Allergy Clin Immunol; 2012 Feb; 129(2):413-9. PubMed ID: 22004944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
    Moingeon P; Mascarell L
    Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.